Detalhe da pesquisa
1.
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.
Blood
; 131(9): 955-962, 2018 03 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29255066
2.
Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.
Blood
; 133(9): 990-992, 2019 02 28.
Artigo
Inglês
| MEDLINE | ID: mdl-30593446
3.
Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia.
Invest New Drugs
; 30(3): 1121-31, 2012 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-21519855
4.
Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
Lancet Haematol
; 9(1): e14-e25, 2022 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-34971577
5.
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
J Clin Oncol
; 30(22): 2776-82, 2012 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22753910